Evidence map›Paper›PMID 35548345›Full record

ArticleFrontiers in pharmacology2022

Bilirubin Improves Gap Junction to Alleviate Doxorubicin-Induced Cardiotoxicity by Regulating AMPK-Axl-SOCS3-Cx43 Axis.

Siqi Zhang, Yixin Fan, Binbin Zheng, Yu Wang, Chen Miao, Yue Su, Kun Li, Yan E, Xueli Wang, Xueming He and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The role and mechanism of heme oxygenase-1 in arrhythmias.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Siqi ZhangDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yixin FanDepartment of Pharmacy, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Binbin ZhengDepartment of Pharmacy, Xinghua People's Hospital, Taizhou, China.
Yu WangJiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Chen MiaoDepartment of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yue SuJiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Kun LiJiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Yan EJiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Xueli WangCenter for Clinical Research and Translational Medicine, The Affiliated Lianyungang Oriental Hospital of Kangda College of Nanjing Medical University, Lianyungang, China.
Xueming HeCenter for Clinical Research and Translational Medicine, The Affiliated Lianyungang Oriental Hospital of Kangda College of Nanjing Medical University, Lianyungang, China.
Xuefeng WuState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Chenjie XuDepartment of Anesthesiology and Pain, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yulin TangDepartment of Pharmacy, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Wen-Tao LiuDepartment of Pharmacy, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Xiangqing KongDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Liang HuJiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNLianyungang Oriental Hospital · CNNanjing University · CNXintai People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin induces severe cardiotoxicity, accompanied by the high level of bilirubin in the blood. The conventional wisdom is that bilirubin is considered as a marker of liver damage. By contrast, here we aim to explore the potential protective effect of bilirubin on doxorubicin-induced cardiotoxicity, and investigate the mechanism for drug development. Doxorubicin was used to establish cardiotoxicity model

Indexed as

AMPKbilirubincardiotoxicityCx43 gap junctiondoxorubicinSOCS3

Identifiers

PMID35548345
PMCPMC9082937
OpenAlexW4224444580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.